These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 21893653

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM, Waugh J, Noble S.
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [Abstract] [Full Text] [Related]

  • 23. Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis.
    Harun SN, Holford NHG, Grimwood K, Wainwright CE, Hennig S, Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group.
    Thorax; 2019 Aug; 74(8):740-748. PubMed ID: 31203197
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K.
    J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
    [Abstract] [Full Text] [Related]

  • 28. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.
    Vidya P, Smith L, Beaudoin T, Yau YC, Clark S, Coburn B, Guttman DS, Hwang DM, Waters V.
    Eur J Clin Microbiol Infect Dis; 2016 Jan; 35(1):67-74. PubMed ID: 26492874
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.
    Paediatr Drugs; 2007 Jan; 9 Suppl 1():21-31. PubMed ID: 17536872
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
    Ang JY, Abdel-Haq N, Zhu F, Thabit AK, Nicolau DP, Satlin MJ, van Duin D.
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5627-30. PubMed ID: 27664282
    [Abstract] [Full Text] [Related]

  • 33. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
    Kernen Y, Sauty A, Roulet M.
    Rev Med Suisse; 2005 Mar 02; 1(9):637-8, 640. PubMed ID: 15813341
    [Abstract] [Full Text] [Related]

  • 34. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC, Brown R, Sacco P, Zhang J.
    J Med Econ; 2010 Mar 02; 13(3):492-9. PubMed ID: 20670159
    [Abstract] [Full Text] [Related]

  • 35. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T.
    Clin Chest Med; 2007 Jun 02; 28(2):307-18. PubMed ID: 17467550
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL.
    Paediatr Drugs; 2007 Jun 02; 9 Suppl 1():11-20. PubMed ID: 17536871
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
    Med Lett Drugs Ther; 2014 Jun 23; 56(1445):51-2. PubMed ID: 24956309
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.